Shiv Sena leader Sushil Kumar Jain relinquishes Hindutva, embraces Islam

Bengaluru, Mar 22: The Karnataka government on Sunday afternoon announced that 9 districts in the State will be under lock down till March 31, barring essential services. It also announced imposition of Section 144 across the state for 3 hours - between 9 p.m. (when the "Janata curfew" will end) to 12 midnight.

The nine COVID-19-affected districts are Bengaluru, Bengaluru Rural, Mysuru, Kodagu, Dakshina Kannada (Mangaluru), Dharwad, Belagavi, Kalaburgi and Chikkablapur.

Announcing these measures after attending a meeting chaired by Chief Minister B. S Yeddyurappa, Home Minister Basavaraj Bommai said that there will be no commercial activity in these districts till March 31.

Inter-district movement, including public transport will be restricted. "Public transport will not work across the state tomorrow too. Air conditioned buses will be stopped till March 31," he added. He also clarified that while public transport, including KSRTC, BMTC and Namma Metro, will be withdrawn, private transport services such as cabs and autos will continue to ply.

According to Mr. Bommai, the State government will put in place further measures next week depending on how the situation will unfold in the State and the neighbouring States.

"Government offices will be operational in the State, including in the nine COVID 19-affected districts. As per the current schedule, the legislature sessions will also continue. Pourakarmikas will be working at 50% strength," he added.

Bengaluru, Feb 6: Karnataka government has launched an aggressive awareness campaign against the novel coronavirus across the state with a special focus on its bordering areas in wake of the three confirmed cases of the deadly pathogen in neighbouring Kerala.

According to Health Commissioner Pankaj Kumar Pandey, "All necessary information on the virus, its symptoms and precautions are being announced at public places like bus stops via radio from time to time."

“A video regarding the same is also being played in 500 cinema halls, advising masses to take precautions," he said.

Bengaluru, Mar 11: The Insurance Regulatory Authority of India has asked insurers to settle all claims related to coronavirus expeditiously under existing health policies that provide for treatment of hospitalisation expenses.

It has also asked insurers to design products covering the cost of treatment of coronavirus that has fast spread across the world and also resulted in increasing number of infections in India. There has been over 3,000 deaths globally and 58 cases tested positive in India.

In order to provide need-based health insurance coverage, insurers are intro ducing products for various specific diseases, including vector borne diseases. "For the purpose of meeting health insurance requirements of various sections, insurers are advised to design products covering the costs of treatment for coronavirus," the IRDAI said in a circular.

The regulator said that under existing health insurance policies where hospitalisation is covered, not only the cases related to coronvirus disease (COVID-19) shall be expeditiously handled, but all the costs of admissible medic al expenses during the course of treatment, including the treatment during quarantine period, should be settled in accordance to the applicable terms and conditions of policy contract and the extant regulatory framework.

This would bring much needed relief to policy holders some of whom were facing difficulty in getting coverage for treatment takers to coronavirus. In the absence of clear information, a few hospitals were reportedly denying for forward such claims of policy holders to the insurers.

IRDAI has now said that all the claims reported under COVID-19 shall be thoro ughly reviewed by review committee before repudiating the claims. This would prevent blanket rejection of such claims.

But to get full claim for treatment of coronavirus, industry experts said, a person should be hospitalised at least for 24 hours. Most insurers do not c over outpatient treatment.